ライフサイエンスコーパス: apathy

1 Behaviour in FTD-ALS was dominated by apathy.

2 of which were dystonia, speech disorder, and apathy.

3 behavioural dysfunction with high levels of apathy.

4 thway in cognitively intact PD patients with apathy.

5 diminished sustained attention, fatigue, and apathy.

6 sion was only 2.62% compared with 14.60% for apathy.

7 observed here might be a useful correlate of apathy.

8 enia patients with high versus low levels of apathy.

9 isorders showing frontal lobe involvement in apathy.

10 ported the role of the anterior cingulate in apathy.

11 nsions of affective flattening and avolition-apathy.

12 cipants (176 cognitively normal), 52 had MBI-apathy.

13 E=0.10, p=0.013) was associated with greater apathy.

14 manifest symptoms of depression, anxiety and apathy.

15 to costs would underpin Huntington's disease apathy.

16 ntribute to motivational deficits, including apathy.

17 activities of daily living-predict emotional apathy.

18 ere included; 20 participants (50%) also had apathy.

19 reduction on Y-BOCS) reporting increases in apathy.

20 1) were additionally associated with greater apathy.

21 posterior cortical areas could contribute to apathy.

22 e closely associated with the development of apathy.

23 .004) and were unchanged in patients without apathy.

24 mited understanding of mechanisms underlying apathy.

25 ased initiation apathy and reduced emotional apathy.

26 e on medication, and assessed in relation to apathy.

27 inically significant) with depression (20%), apathy (15%), and irritability (15%) being most common.

28 1.6%]), slowness (23 [71.9%] vs 95 [26.2%]), apathy (23 [71.9%] vs 189 [52.1%]), and motor deteriorat

29 ial symptoms among symptomatic patients were apathy (23%), disinhibition (18%), memory impairments (1

30 Apathy (27%), depression (24%), and agitation/aggression

31 ementia, the most frequent disturbances were apathy (36%), depression (32%), and agitation/aggression

32 Depression (56% versus 17%, P = 0.0003), apathy (40% versus 4%, P < 0.0001), disinhibition (16% v

33 Apathy (64%), moderate-severe anxiety (57%), and severe

34 parkinsonism (95.2% of patients), depression/apathy (71.4%), respiratory symptoms (66.7%) and weight

35 as part of mild behavioural impairment (MBI-apathy), a syndrome defined by emergent and persistent N

36 Huntington's disease is also associated with apathy, a loss of motivation and failure to engage in go

37 Additionally, apathy across participants was associated with bias towa

38 showed a greater mean reduction in avolition-apathy (adjusted mean [SE], 1.66 [0.31] vs 2.81 [0.34],

39 ical assessments evaluated depression (GDS), apathy (AES), cognitive status (MMST), mobility (TUG), h

40 Four DLB patients with apathy and 4 DLB patients without apathy were identified

41 ToM deficit also displayed higher levels of apathy and a naming deficit.

42 e aimed to determine the association between apathy and AD biomarkers when it occurred as part of the

43 nson's Progression Markers Initiative cohort.Apathy and anhedonia were measured using a composite sco

44 ate psychiatric symptoms such as depression, apathy and anxiety are risk factors for or prodromal sym

45 pathology may drive the development of both apathy and anxiety in very early stages of AD, largely i

46 served for NMSScale total score and its mood/apathy and attention/memory domains.

47 functioning and psychiatric symptoms (e.g., apathy and avolition), but not psychotic symptoms (e.g.,

48 ng correlation was found between measures of apathy and both attenuated P3 amplitude and viewing dura

49 etween latent cognitive processes altered in apathy and brain structure and connectivity in a priori

50 Moreover, effective treatments for apathy and cognitive decline do not currently exist.

51 had lower performance IQ scores than the low apathy and comparison groups.

52 This study investigated whether apathy and depression can be distinguished in small vess

53 studied in order to interpret the degree of apathy and depression found within the small vessel dise

54 symptoms, e.g. gait and balance impairment, apathy and depression in Alzheimer's disease patients su

55 ession and cognitive impairment; and (ii) if apathy and depression make independent contributions to

56 were used to predict dementia using baseline apathy and depression scores in both datasets.

57 Change in apathy and depression was used to predict dementia in a

58 n of behavioral profiles, differentiation of apathy and depression, characterization of risk factors

59 regions of white matter were associated with apathy and depression, controlling for age, gender and c

60 sel disease is associated with high rates of apathy and depression, thought to be caused by a disrupt

61 re not blood loss and infection but, rather, apathy and disdain toward women.

62 Apathy and disinhibition are common and highly distressi

63 Apathy and disinhibition atrophy networks resemble known

64 ocampal sclerosis, the findings of increased apathy and disinhibition merit further investigation.

65 ia (FTD) is a disease of high heterogeneity, apathy and disinhibition present in all subtypes of FTD

66 sdiagnostic studies, measuring subdomains of apathy and disinhibition, and examining different units

67 egative symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathologi

68 This accommodates the commonalities of apathy and impulsivity across disorders and reveals thei

69 The ability to measure the components of apathy and impulsivity and their associated neural corre

70 Apathy and impulsivity are common and disabling conseque

71 Apathy and impulsivity are debilitating conditions assoc

72 Apathy and impulsivity are expressed in a wide range of

73 Measures of apathy and impulsivity frequently loaded onto the same c

74 o determine the neurocognitive components of apathy and impulsivity in frontotemporal lobar degenerat

75 tigated the relationship between measures of apathy and impulsivity in young adults.

76 We derived dimensions of apathy and impulsivity using principal component analysi

77 The frequency and characteristics of apathy and impulsivity were determined by neuropsycholog

78 Although apathy and impulsivity were positively correlated in que

79 Apathy and impulsivity were present across diagnostic gr

80 obar degeneration provides new insights into apathy and impulsivity, and the need for a joint therape

81 ventory-Revised and two targeted measures of apathy and impulsivity.

82 mutation presented a contrasting picture of apathy and inertia.

83 for subgroups (r = 0.49, p = 0.04), whereas apathy and left anterior cingulate NFTs showed a signifi

84 esent in some patients with ALS, manifest as apathy and loss of awareness.

85 f medication effects on clinical measures of apathy and motor dysfunction.

86 onsignificant trend toward less worsening in apathy and no significant between-group differences in a

87 mediator of the association between baseline apathy and persistence of depression.

88 Elucidating brain networks associated with apathy and poor treatment outcomes can inform interventi

89 nsitivity may be a contributory mechanism to apathy and provide potential new clinical measures for i

90 aggression, obsessive/compulsive behaviours, apathy and psychosis.

91 y a specific profile of increased initiation apathy and reduced emotional apathy.

92 pathway complement consumption and provoked apathy and reduced nociceptive responses in rats.

93 nxiety or depression, cognitive decline, and apathy), and additional features (fatigue, insomnia, ano

94 t developed increasing reasoning difficulty, apathy, and disinhibition.

95 with poor quality of life, disease severity, apathy, and exposure to antimuscarinics.

96 amily, knowledge, information, media, grief, apathy, and fear.

97 tex, and higher PBA-HD scores on depression, apathy, and irritability (range, P = 0.01-0.005).

98 manifest disproportionate disinhibition and apathy, and may exhibit compulsions.

99 demonstrated increased rates of depression, apathy, and other behavioural symptoms in the mildly sym

100 e mania, bipolar disorder, anxiety disorder, apathy, and pathological crying.

101 horizontal and vertical saccades, dysphagia, apathy, and progressive cognitive decline, which led to

102 itive symptoms, such as anxiety, depression, apathy, and psychosis, that impair daily living.

103 t non-cognitive features include depression, apathy, and psychosis.

104 sease course), mood (especially, depression, apathy, and suicidality), personality and behavior (espe

105 ease focusing on symptoms of depressed mood, apathy, anhedonia, or anergia.

106 ences, even in superficially related traits (apathy-anhedonia and anxiety-compulsive checking) reliab

107 Appearance and subsequent worsening of apathy/anhedonia symptoms began on average 2 years after

108 triatal DAT specific binding ratio (SBR) and apathy/anhedonia symptoms, which emerged as PD progresse

109 The primary outcome for apathy (Apathy Evaluation Scale-Clinician) and secondary

110 enetic liability to cognitive impairment and apathy appears to be distinct from other psychiatric sym

111 ral symptoms of sickness such as fatigue and apathy are debilitating and can prevent recuperation.

112 Factor analyses showed that empathy and apathy are distinct constructs, but that affective empat

113 Here, we asked whether people with apathy are more sensitive to costs of actions (physical

114 Mechanisms underlying apathy are poorly understood and clinically we lack robu

115 radykinesia) and motivational deficit (i.e., apathy) are hallmarks of Parkinson's disease (PD).

116 t is, 'negativity bias' (negative valence), 'apathy' (arousal) and 'emotional dysregulation' (cogniti

117 variable measurement scales and the focus on apathy as a unitary concept.

118 ith anosognosia demonstrated faster onset of apathy as compared to patients without anosognosia.

119 n carriers was behavioural variant FTLD with apathy as the dominant feature.

120 s of HD in this European HD population, with apathy as the most frequent symptom.

121 Apathy, as a syndrome, has recently been associated with

122 nergisation'-the loss of which is central in apathy-as a core executive function.

123 also improved on self-reported and caregiver apathy assessments (P = 0.03 and P = 0.02, respectively)

124 er evidence of effort hypersensitivity, with apathy associated with a faster drift rate towards rejec

125 that the interindividual variability of mood/apathy, attention/memory, and sleep outcomes after subth

126 ual framework for understanding pathological apathy based on this current understanding of normal mot

127 gene variant carriers (>50% patients), with apathy being one of the most common and severe symptoms

128 ine was associated with increasing levels of apathy (beta = -0.284, p = .005) and anxiety (beta = -0.

129 d delay sensitivity was also associated with apathy, both when analysing raw choice and drift rate, w

130 ree patients, memory loss was accompanied by apathy but no other behavioural changes.

131 in small vessel disease are associated with apathy but not directly with depressive symptoms.

132 t both drugs improved cognitive function and apathy, but had a stronger effect when used in combinati

133 These results suggest that apathy, but not depression, in small vessel disease is r

134 Apathy, but not depression, may be a prodromal symptom o

135 arkinson's disease, which was more marked in apathy, but not predictive of their individual apathy se

136 dication might be an effective treatment for apathy by increasing reward sensitivity, independent of

137 can be driven by goals, hence accounting for apathy cases in clinics.

138 Apathy, characterized by diminished will or initiative a

139 may share a microvascular origin, including apathy, cognitive impairment, dementia, and stroke.

140 as significantly reduced in PD patients with apathy compared with nonapathetic patients and healthy c

141 d behavioural changes such as disinhibition, apathy, compulsiveness and loss of empathy were the most

142 interest in the neuropsychiatric syndrome of apathy, conceptualised as a loss of motivation manifesti

143 As expected, apathy correlated positively with impulsivity across all

144 In contrast, Parkinson's patients without apathy demonstrated significantly increased activation a

145 inally, we relate these findings to clinical apathy, demonstrating the homologies between this basic

146 ips between median fractional anisotropy and apathy, depression and cognitive impairment; and (ii) if

147 tions have evolved for psychosis, agitation, apathy, depression, and disinhibition in NDDs.

148 gnosis of change across 10 BPSDs (agitation, apathy, depression, delusions, disinhibition, auditory h

149 and completed cognitive testing, measures of apathy, depression, quality of life and diffusion tensor

150 urs examined, 4 correlated with tissue loss: apathy, disinhibition, eating disorders and aberrant mot

151 ignificant correlation was found between the apathy/disinhibition scores and functional connectivity

152 studies, we revise a neurocircuitry model of apathy divided along three subcomponents (cognition/plan

153 as moderate evidence of Huntington's disease apathy drifting faster towards the immediately available

154 activation persistence negatively related to apathy, especially anhedonia, and to anhedonia at T3.

155 asked to complete the DAS, the standardised Apathy Evaluation Scale, and the Geriatric Depression Sc

156 The primary outcome for apathy (Apathy Evaluation Scale-Clinician) and secondary outcome

157 o measure 3 neurologically based subtypes of apathy: Executive, Emotional and Initiation.

158 lation has in some patients led to increased apathy following surgery.

159 The high apathy group had lower performance IQ scores than the lo

160 lling of the patient's choices confirmed the apathy group made decisions that were indifferent to the

161 The high apathy group scored lower than comparison subjects on ra

162 Only the high apathy group showed significantly reduced bilateral fron

163 with participants without apathy, those with apathy had lower structural connectivity in the splenium

164 Apathy has profound consequences, such as functional imp

165 Levels of apathy have been consistently shown to correlate with th

166 ation (hazard ratio=3.06, 95% CI=1.89-4.93), apathy (hazard ratio=2.26, 95% CI=1.49-3.41), anxiety (h

167 ients with anosognosia had a faster onset of apathy (HR: 2.78, 95% CI: 1.37-5.62, p = 0.01) compared

168 e components, interpreted as reflecting: (i) apathy; (ii) challenging behaviours; and (iii) activitie

169 Methylphenidate improved apathy in a group of community-dwelling veterans with mi

170 ral symptom by examining the substructure of apathy in ALS and to determine the reliability and valid

171 Apathy in ALS is characterised by a specific profile of

172 asure for the assessment of multidimensional apathy in ALS.

173 s to study the effects of methylphenidate on apathy in Alzheimer's disease.

174 In sum, apathy in both aMCI/pAD and PD is associated with altera

175 del free analysis of choice data showed that apathy in both groups was associated with reduced incent

176 However, the significance of MBI-apathy in dementia-free persons, including its associati

177 We reviewed all neuroimaging studies of apathy in frontotemporal dementia (FTD) attempting to re

178 Apathy in FTD is most robustly associated with atrophy,

179 low the progression of cognitive decline and apathy in neurological conditions where sleep is disorde

180 uilding upon this work, we hypothesized that apathy in Parkinson's disease should be associated with

181 ensates against symptomatic manifestation of apathy in Parkinson's disease.

182 and was associated with a small reduction in apathy in patients with frontotemporal dementia.

183 vation and reward sensitivity in relation to apathy in patients with Parkinson's disease.

184 n making may lead to the common phenotype of apathy in PD.

185 Including apathy in predictive models of dementia improved model f

186 features were depression and anxiety in CBS, apathy in PSP, with sleep disturbances common in PD.

187 Cognitive decline and apathy in R6/2 mice can be improved with sleeping drugs,

188 r degeneration was associated with increased apathy, increased disinhibition, and decreased psychosis

189 e trend was driven by changes in measures of apathy independent of dementia severity.

190 er, Mini-Mental State Examination score, and apathy/indifference, did not affect the rate of function

191 ally discriminating features (disinhibition, apathy/inertia, loss of sympathy/empathy, perseverative/

192 e to modify the bvFTD diagnostic criteria of apathy/inertia.

193 Apathy is a common and disabling complication of Parkins

194 Apathy is a common behavioral problem in Alzheimer's dis

195 Apathy is a common negative symptom in schizophrenia.

196 Apathy is a common neuropsychiatric symptom (NPS) in Alz

197 Apathy is a common symptom across a wide range of neurod

198 Apathy is a common syndrome observed in many neurologica

199 Apathy is a debilitating and under-recognized condition

200 Apathy is a debilitating feature of many neuropsychiatri

201 Apathy is a prominent symptom of amyotrophic lateral scl

202 Apathy is a symptom shared among many neurological and p

203 Although apathy is a well-recognised symptom in adults living wit

204 Apathy is also consistently associated with neuroimaging

205 Here we investigated the hypothesis that apathy is associated with disrupted decision making in e

206 In dementia, apathy is associated with higher morbidity, mortality an

207 Apathy is found to relate positively to the degree of or

208 In this article, we propose that apathy is not merely the result of actions becoming unde

209 Apathy is one of the core features of behavioural varian

210 Apathy is one of the most common and debilitating nonmot

211 Apathy is prevalent among individuals with late-life dep

212 tivation, whilst a cross-cutting approach to apathy is still informative from a framework perspective

213 Schizophrenia patients with low apathy levels (N=18) and high apathy levels (N=20) and 1

214 ients with low apathy levels (N=18) and high apathy levels (N=20) and 12 healthy comparison subjects

215 the impact of surgery and lesion location on apathy levels is clearly warranted using objective, quan

216 avoid pathogens, here we describe a peculiar apathy-like behavior towards PA14 in animals with consti

217 ically induced increased effort-sensitivity, apathy-like symptoms through a cytokine-sensing brainste

218 ehavioral symptoms, including disinhibition, apathy, loss of empathy, perseverative behavior, and hyp

219 bitofrontal cortex in AD, whereas increasing apathy may relate to greater NFT burden in the anterior

220 re stratified by NPS status (MBI-apathy, non-apathy MBI, non-MBI NPS and no-NPS) based on the Neurops

221 res for improved diagnosis and monitoring of apathy.media-1vid110.1093/brain/aww188_video_abstractaww

222 nistered self-report measures of empathy and apathy-motivation to a large sample of healthy people (n

223 Delusion, hallucination, agitation, anxiety, apathy, motor-disturbances, night-time behavior and eati

224 nitiative were stratified by NPS status (MBI-apathy, non-apathy MBI, non-MBI NPS and no-NPS) based on

225 ese processes is likely to contribute to the apathy observed in patients after injury to the frontal

226 Moderate to severe apathy occurred in 28.1% of the participants, whereas mo

227 Apathy occurs frequently, and with substantial impact on

228 mpal sclerosis was associated with increased apathy (odds ratio, 2.60; 95% CI; 1.86-3.66, false disco

229 The unacceptable apathy of governments and funders of global health must

230 ential impact of syndromes such as mania and apathy on rehabilitation efforts or pathological crying

231 s, patients showed a significant increase in apathy on the Initiation subscale, and were significantl

232 Apathy, on the other hand, was associated with a blunted

233 area including (i) the assessment of either apathy or impulsivity alone, despite their frequent co-e

234 were found to exhibit a higher frequency of apathy (OR, 1.89; 95% CI, 1.09-3.78; P = .03), nighttime

235 nguishing features between the 2 groups were apathy (OR, 4.53; 95% confidence interval [CI], 3.11-6.6

236 ood disorders were associated with increased apathy (OR=2.78, 95% CI 1.083 to 7.169).

237 Apathy, or loss of motivation, is a prominent syndrome a

238 es were significantly lower in patients with apathy (P = 0.004) and were unchanged in patients withou

239 n emergence at T1 negatively correlated with apathy, particularly asociality and avolition.

240 and its emergence negatively correlated with apathy, particularly asociality.

241 ndary outcomes included measures of anxiety, apathy, quality of life, and cognition.

242 al equation modelling results indicated both apathy (r = -0.23, P </= 0.001) and depression (r = -0.4

243 anisotropy was significantly associated with apathy (r = -0.38, P </= 0.001), but not depression (r =

244 Apathy was indexed by Lille Apathy Rating Scale (LARS) scores.

245 (SD) 4.3 (3.2) vs 2.1 (2.1); p=0.001), Lille Apathy Rating Scale (mean (SD) -23.3 (9.6) vs -27.0 (4.7

246 imulation measured by the Person-Environment Apathy Rating-Environment subscale (stimulation clarity,

247 Among psychiatric indicators, apathy ratings specifically showed significant increases

248 Apathy, REM sleep behaviour disorder, anosmia, hypersali

249 nostic importance, the mechanisms underlying apathy remain controversial.

250 The new Dimensional Apathy Scale (DAS) has been specifically designed for pa

251 s found from baseline to 6 months in the NPI apathy score in those receiving methylphenidate compared

252 ed in an improved Neuropsychiatric Inventory apathy score, with an estimated -1.32 points (95% CI -2.

253 in perseveration, which also correlated with apathy scores (R = -0.5, P < 0.001).

254 Baseline apathy scores predicted dementia in SCANS (HR 1.49, 95%

255 ctivity in the thalamus predicted individual apathy severity across both patient groups and exhibited

256 y modulation by incentives was predictive of apathy severity, and independent of motor impairment and

257 athy, but not predictive of their individual apathy severity.

258 he Total Functional Capacity score, but with apathy showing the strongest inverse association.

259 ng recognition of the clinical importance of apathy, significant advances have been made in understan

260 ymptoms that occur in PD such as depression, apathy, sleep disorders (including rapid-eye movement sl

261 Disorders of motivation such as apathy syndrome are highly prevalent across neurological

262 Antidepressant-induced apathy syndrome is reported in a high number of patients

263 y of hyperactivity, psychosis, affective and apathy syndromes.

264 oup had significantly greater improvement in apathy than the placebo group at 4 weeks, 8 weeks, and 1

265 Compared with participants without apathy, those with apathy had lower structural connectiv

266 ontributes to continued misunderstanding and apathy toward fulfilling the regulatory and ethically ob

267 I scores (4.67 [3.21-6.78]), the presence of apathy (UPDRS item 4) (1.94 [1.33-2.82]), a higher levod

268 Increasing apathy was associated with dementia in SCANS (HR 1.53, 9

269 Apathy was associated with GM density loss in the anteri

270 Exploratory analyses revealed that MBI-apathy was associated with higher CSF p-tau181 [5.98% (0

271 Exploratory LME models revealed that MBI-apathy was associated with higher CSF p-tau181 [6.03% (0

272 ed incentivisation by lower rewards, whereas apathy was associated with increased sensitivity to high

273 On voxel-based analysis, apathy was associated with widespread reduction in white

274 In addition, apathy was independently associated with tissue loss in

275 Apathy was indexed by Lille Apathy Rating Scale (LARS) s

276 Apathy was linked to decision inertia, i.e., automatical

277 en that task performance in patients without apathy was no different to the age-matched control subje

278 contrast, above average improvement for mood/apathy was observed in the ventral border region of the

279 Intriguingly, behavioural apathy was reported alongside impulsivity in the majorit

280 MBI-apathy was significantly associated with core AD biomark

281 Apathy was the key neuropsychiatric symptom occurring mo

282 Apathy was the most common behavioural feature, while hy

283 Apathy was the most prevalent NPS, reaching 80% (203 of

284 comparison, loss of goal-direct behaviour or apathy, was associated with changes in the direct pathwa

285 oural disturbance, including impulsivity and apathy, was associated with reduced functionally indepen

286 In contrast, when controlling for apathy, we found no significant relationship between our

287 y clinical signs of parkinsonism, depression/apathy, weight loss, respiratory symptoms, mutations in

288 chsler tests, and cognitive fluctuations and apathy were also assessed.

289 Depressed mood, anhedonia, anergia, and apathy were assessed at baseline using a structured beha

290 Cognitive impairment and apathy were associated with reduced polygenic risk score

291 presenting clinically meaningful symptoms of apathy were compared with nonapathetic PD patients and h

292 ients with apathy and 4 DLB patients without apathy were identified.

293 Depression and avolition-apathy were significantly positively related, and depres

294 ongest predictor of executive and initiation apathy, whereas functional indicators-particularly indep

295 stroke are depression, anxiety, fatigue, and apathy, which each occur in at least 30% of patients and

296 However, six patients endorsed increased apathy with half of the non-responders (e.g., less than

297 and 2, apathy without depression versus non-apathy without depression (80:26), disinhibition versus

298 pecific networks [combined Datasets 1 and 2, apathy without depression versus non-apathy without depr

299 alyses, seven core features were identified: apathy without moderate-severe dysphoria, behavioural di

300 ted symptoms and traits (e.g., anhedonia and apathy), yet no research has explored this issue transdi